Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
暂无分享,去创建一个
Martin Peifer | Daniel Rauh | Lars Ruddigkeit | H. Greulich | Roman K. Thomas | Lars Ruddigkeit | M. Peifer | M. Sos | Y. Yuza | Tzu-Hsiu Chen | J. Heuckmann | D. Rauh | M. Koker | Stefanie Heynck | J. Weiss | Florian Fischer | Mirjam Koker | Stefanie Heynck | Jonathan Weiss | Florian Fischer | Matthäus Getlik | M. Rabiller | Matthäus Getlik | S. Klüter | J. Simard | Jeffrey R Simard | Matthias Rabiller | Sabine Klüter | Tzu-Hsiu Chen | Heidi Greulich | Yuki Yuza | Roman K Thomas | Haridas B Rode | Martin L Sos | Johannes M Heuckmann | Vijaykumar G Pawar | Cecile Reuter | H. Rode | V. Pawar | Cecile Reuter | Mirjam Koker
[1] C. Grütter,et al. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. , 2008, Bioorganic & medicinal chemistry.
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[4] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] William Pao,et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer , 2009, Proceedings of the National Academy of Sciences.
[6] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[7] M. Meyerson,et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors , 2007, Cancer biology & therapy.
[8] Kwok-Kin Wong,et al. HKI-272 in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.
[9] Roman K. Thomas,et al. Systematically linking drug susceptibility to cancer genome aberrations , 2009, Cell cycle.
[10] U. McDermott,et al. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor , 2008, Molecular Cancer Therapeutics.
[11] J. Verweij,et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours , 2007, British Journal of Cancer.
[12] William Pao,et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. , 2009, The Journal of clinical investigation.
[13] P. Jänne,et al. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[14] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[15] M. Meyerson,et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.
[16] M. Meyerson,et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. , 2007, Cancer cell.
[17] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[18] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[19] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.
[20] Laura Tolosi,et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.